Clinical trials: Localized Prostate Cancer
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other…
- Conditions
- Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues
- Trial name
- NCT01050504
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Washington
Prostate Cancer
PD-L1-expressing Regulatory T Cells in Localized Prostate Cancer Patients Undergoing Iodine-125 Permanent Brachytherapy
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer is poorly responsive to immune checkpoint inhibition.
- Trial name
- NCT04369508
- Testing
- permanent brachytherapy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Prostate Cancer
Understanding of Genetics by Men at Risk for Prostate Cancer
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions.
- Trial name
- NCT04550845
- Testing
- Focus group analyses
- Where
- 3 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Prostate Cancer, Radiotherapy Side Effect
Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.
Phase 1-2 study, comparing ultra-hypofractionnated (UH) to a moderately hypofractionnated (MH) radiation therapy, with image guided HDR prostate brachytherapy.
- Conditions
- Prostate Cancer, Radiotherapy Side Effect, Hypofractionation, Brachytherapy
- Trial name
- HYPO-5 (NCT05786742)
- Testing
- grade and compare reported side effects between groups
- Where
- Canada
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
Hemiablative Focal Brachytherapy Pilot Study
Whole gland LDR brachytherapy has been a well established modality of treating low risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs.
- Trial name
- NCT02643511
- Testing
- Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- St George Hospital, Australia
Prostate Cancer
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
This Phase 1 trial will evaluate the safety and tolerability of PSA-Activated PSA-PAH1 in subjects who have shown biochemical failure and have either completed at least one primary radiation therapy for prostate cancer and have…
- Trial name
- NCT00379561
- Testing
- PSA-Activated PSA-PAH1
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
CyberKnife Radiosurgery for Localized Prostatic Carcinoma
Virtual high dose rate (HDR) CyberKnife (CK) prostate treatment has comparable morbidity and efficacy compared with actual prostate HDR treatment, but does it without the catheters and hospital admission.
- Trial name
- NCT01045148
- Testing
- CyberKnife Radiosurgery
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- CyberKnife Centers of San Diego
Prostate Cancer
Evaluation of a Web-based Decision Aid Tool for Prostate Cancer Patients
Patients diagnosed with localized prostate cancer may be eligible for different treatment options. MAASTRO Clinic (MAAStricht Radiation Oncology) developed a web-based decision aid tool for these patients.
- Trial name
- ProDecA (NCT03278197)
- Testing
- Interviews, Treatmentchoice Decisional Tool, Questionnaires
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Maastricht Radiation Oncology